Open AccessAssociation of Fibroblast Growth Factor-23 (FGF-23) With Incident Frailty in HIV-Infected and HIV-Uninfected Individuals
Author(s) -
Ruibin Wang,
Michael G. Shlipak,
Joachim H. Ix,
Todd T. Brown,
Lisa P. Jacobson,
Frank J. Palella,
Jordan E. Lake,
Susan L. Koletar,
Richard D. Semba,
Michelle M. Estrella
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001868
Subject(s) - serostatus , medicine , hazard ratio , fibroblast growth factor 23 , confidence interval , multicenter aids cohort study , risk factor , cohort , human immunodeficiency virus (hiv) , immunology , viral load , antiretroviral therapy , parathyroid hormone , calcium
In the Multicenter AIDS Cohort Study, we examined whether fibroblast growth factor-23 (FGF-23), a bone-derived phosphaturic hormone involved in bone metabolism, is associated with incident frailty. Furthermore, we examined whether this association differs by HIV serostatus and race.